Form 8-K - Current report:
SEC Accession No. 0001493152-21-025275
Filing Date
2021-10-13
Accepted
2021-10-13 10:01:19
Documents
14
Period of Report
2021-10-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38093
2 ex99-1.htm EX-99.1 15813
  Complete submission text file 0001493152-21-025275.txt   273576

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lixt-20211008.xsd EX-101.SCH 3522
4 XBRL DEFINITION FILE lixt-20211008_def.xml EX-101.DEF 26600
5 XBRL LABEL FILE lixt-20211008_lab.xml EX-101.LAB 36572
6 XBRL PRESENTATION FILE lixt-20211008_pre.xml EX-101.PRE 25218
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5271
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 211320337
SIC: 2834 Pharmaceutical Preparations